Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

被引：2
|
作者：
Eliason, Laurie
Correll, Julia
Martin, Mona
Cardellino, Anna
Opalinska, Joanna
Piontek, Trisha
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
    Ferron-Brady, Geraldine
    Taylor, Adekemi
    Kaullen, Josh
    Polireddy, Kishore
    McKeown, Astrid
    Sule, Neal
    Struemper, Herbert
    BLOOD, 2023, 142
  • [32] Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
    Hungria, Vania
    Robak, Pawel
    Hus, Marek
    Fu, ChengCheng
    Zherebtsova, Vera
    Ward, Christopher
    de Almeida, Ana Carolina
    Ho, P. Joy
    Hajek, Roman
    Cerchione, Claudio
    Pirooz, Nick
    McKeown, Astrid
    Baig, Hena
    Eccersley, Lydia
    Pompilus, Farrah
    McNamara, Simon
    Lin, Chee Paul
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Victoria Mateos, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S568 - S568
  • [33] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [34] Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    BLOOD, 2020, 136
  • [35] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
    Callander, Natalie S.
    Richardson, Paul G.
    Hus, Marek
    Ribrag, Vincent
    Lopez, Joaquin Martinez
    Kim, Kihyun
    Lee, Jae Hoon
    Dimopoulos, Meletis
    Schjesvold, Fredrik
    Facon, Thierry
    Jo, Jae-Cheol
    Min, Chang-Ki
    Mielnik, Michal
    Cheng, Shinta
    Smith, L. Mary
    Breitbach, Caroline J.
    Brawley, Chris
    Sembhi, Harjeet
    LaMacchia, John
    Hakim, Shawn
    Kremer, Brandon E.
    Grosicki, Sebastian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
  • [36] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Biswas, Swethajit
    Holkova, Beata
    Jackson, Nicola
    Netherway, Thelma
    Paul, Sofia
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Shelton, Chris
    de Oca, Rocio Montes
    Ahlers, Christoph Matthias
    Ballas, Marc S.
    Paul, Elaine Marie
    Gupta, Ira
    Opalinska, Joanna
    Luptakova, Katarina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul G.
    Trudel, Suzanne
    Callander, Natalie S.
    Nooka, Ajay
    Song, Kevin
    Uttervall, Katarina
    Minnema, Monique C.
    Rodriguez-Otero, Paula
    Struemper, Herbert
    Yeakey, Anne
    de Oca, Rocio Montes
    Smith, L. Mary
    Jackson, Nicola
    Kaisermann, Morrys
    Im, Ellie
    Basile, Frank G.
    Ahlers, Christoph M.
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
  • [39] DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
    Eliason, Laurie
    Opalinska, Joanna
    Martin, Mona L.
    Correll, Julia
    Gutierrez, Benjamin
    Popat, Rakesh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Collins, J.
    van Noort, M.
    Rathi, C.
    Post, T.
    Struemper, H.
    Jewell, R.
    Ferron-Brady, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S16 - S17
12345